Avelumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Merkel Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (2)
JP
  • Treatment of unresectable Merkel cell carcinoma
Product first approved 2017PMDA
EU
  • Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Bavencio is indicated as monotherapy for the first?line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum?based chemotherapy.
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (19)
Merkel Cell Carcinoma
NCT03271372 · University of Washington
2017-12-19 – 2029-02-18 · Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
What this study did
Renal Cell Carcinoma
NCT03013946 · AIO-Studien-gGmbH
2017-01-18 – 2024-01-16 · Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
What this study did
Urothelial Carcinoma
NCT04637594 · Alliance for Clinical Trials in Oncology
2022-05-27 – 2030-09 · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma
What this study did
NCT05092958 · National Cancer Institute (NCI)
2022-06-03 – 2029-07-15 · Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
What this study did
NCT05059522 · Pfizer
2021-09-29 – 2026-12-31 · Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
What this study did
Other / comorbidity
NCT02999087 · Groupe Oncologie Radiotherapie Tete et Cou
2017-09-14 – 2027-12 · HNSCC
What this study did
Avelumab Program Rollover Studyactive not recruiting
NCT03815643 · EMD Serono Research & Development Institute, Inc.
2019-03-22 – 2026-11-24 · Solid Tumors
What this study did
NCT02926196 · Istituto Oncologico Veneto IRCCS
2016-06-17 – 2025-10-09 · Triple Negative Breast Neoplasms
What this study did
NCT02576574 · EMD Serono Research & Development Institute, Inc.
2015-10-29 – 2024-01-29 · First Line Non-Small Cell Lung Cancer
What this study did
NCT03827044 · Royal Marsden NHS Foundation Trust
2018-08-31 – 2022-01-05 · POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon Cancer
What this study did
NCT03642132 · Pfizer
2018-07-19 – 2021-12-22 · Ovarian Cancer
What this study did
NCT02625610 · EMD Serono Research & Development Institute, Inc.
2015-12-24 – 2021-06-03 · Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
What this study did
NCT02718417 · Pfizer
2016-05-19 – 2019-05-16 · Ovarian Cancer
What this study did
Phase 2 (120)
Merkel Cell Carcinoma
NCT03228667 · ImmunityBio, Inc.
2018-12-11 – 2030-12-31 · Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
What this study did
NCT04291885 · Melanoma and Skin Cancer Trials Limited
2020-10-26 – 2030-04-30 · Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Merkel Cell Carcinoma, Stage III, Neuroendocrine Tumors, Carcinoma Neuroendocrine Skin
What this study did
NCT05947500 · National Cancer Institute (NCI)
2024-05-21 – 2028-01-01 · Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma
What this study did
NCT04792073 · Memorial Sloan Kettering Cancer Center
2021-03-08 – 2027-03 · Merkel Cell Carcinoma
What this study did
NCT04874831 · 4SC AG
2021-11-01 – 2025-09 · Merkel Cell Carcinoma
What this study did
NCT04393753 · 4SC AG
2020-10-13 – 2024-02-26 · Merkel Cell Carcinoma
What this study did
NCT03853317 · ImmunityBio, Inc.
2020-02-19 – 2022-09-19 · Merkel Cell Carcinoma
What this study did
Renal Cell Carcinoma
NCT05176288 · Bradley A. McGregor, MD
2024-05-31 – 2027-08-31 · Advanced Clear Cell Renal Cell Carcinoma
What this study did
NCT03341845 · The Netherlands Cancer Institute
2018-03-28 – 2025-01-31 · Renal Cell Carcinoma
What this study did
NCT04698213 · Consorzio Oncotech
2020-10-07 – 2024-10 · Renal Carcinoma Metastatic
What this study did
NCT04068831 · Memorial Sloan Kettering Cancer Center
2019-08-22 – 2023-12-06 · Metastatic Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma, Succinate Dehydrogenase Deficient Renal Cell Carcinoma
What this study did
NCT03035630 · Guru Sonpavde
2017-05-23 – 2020-12 · Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
What this study did
Urothelial Carcinoma
NCT07460245 · Gruppo Oncologico Italiano di Ricerca Clinica
2026-06 – 2030-12 · Urothelial Carcinoma
What this study did
NCT03547973 · Gilead Sciences
2018-08-13 – 2030-04 · Metastatic Urothelial Cancer
What this study did
NCT07225374 · Samsung Medical Center
2025-09-16 – 2029-07-02 · Upper Tract Urothelial Carcinoma
What this study did
NCT05574504 · AdventHealth
2023-05-08 – 2028-11 · Metastatic Cancer, Urothelial Carcinoma
What this study did
NCT06892860 · Queen Mary University of London
2021-12-16 – 2027-12-22 · Urinary Bladder Neoplasms
What this study did
NCT03744793 · M.D. Anderson Cancer Center
2019-04-11 – 2027-01-31 · Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Metastatic Urothelial Carcinoma, MTAP Negative
What this study did
NCT05327530 · EMD Serono Research & Development Institute, Inc.
2022-08-17 – 2027-01-22 · Locally Advanced or Metastatic Urothelial Carcinoma
What this study did
NCT04848519 · Emory University
2021-05-20 – 2026-12-04 · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
What this study did
NCT05600127 · Erasmus Medical Center
2022-12-01 – 2026-12 · Urothelial Carcinoma
What this study did
NCT06424717 · EMD Serono Research & Development Institute, Inc.
2024-08-16 – 2026-01-27 · Urothelial Carcinoma
What this study did
NCT04701918 · Massachusetts General Hospital
2021-06-04 – 2025-12-01 · Metastatic Urothelial Carcinoma, Bladder Cancer
What this study did
NCT04678362 · Centre Francois Baclesse
2021-06-01 – 2025-12 · Urothelial Carcinoma
What this study did
NCT04871529 · SWOG Cancer Research Network
2022-08-10 – 2024-06-26 · Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
What this study did
NCT04887831 · G1 Therapeutics, Inc.
2021-06-04 – 2024-03-01 · Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia, Metastatic Bladder Cancer
What this study did
NCT06018116 · CHU de Quebec-Universite Laval
2023-11-07 – 2024-02-12 · Metastatic Urothelial Carcinoma
What this study did
NCT04322643 · Case Comprehensive Cancer Center
2020-03-23 – 2023-04-17 · Urothelial Carcinoma
What this study did
NCT05107427 · 4D pharma plc
2022-03-01 – 2023-04 · Urothelial Carcinoma
What this study did
NCT03472560 · Pfizer
2018-05-02 – 2023-02-09 · Non-Small Cell Lung Cancer, Urothelial Cancer
What this study did
NCT03390595 · Associació per a la Recerca Oncologica, Spain
2018-05-17 – 2022-08-31 · Metastatic Urothelial Cancer
What this study did
NCT03891238 · Consorzio Oncotech
2019-02-06 – 2021-09-15 · Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer
What this study did
NCT03617913 · Mayo Clinic
2018-09-19 – 2020-07-27 · Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8, Stage II Urethral Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Urethral Urothelial Carcinoma
What this study did
Other / comorbidity
NCT07110038 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2025-12-16 – 2030-11 · Penile Squamous Cell Carcinoma (PSCC)
What this study did
NCT04341181 · Ulrik Lassen
2020-08-24 – 2030-04-30 · Cancer, Tumors, Neoplasms, Neoplasia
What this study did
NCT06518564 · Panagiotis Konstantinopoulos, MD, PhD
2024-11-14 – 2029-08-31 · Endometrial Cancer, ARID1A Gene Mutation, Recurrent Endometrial Carcinoma
What this study did
NCT06640725 · Groupe Oncologie Radiotherapie Tete et Cou
2025-01-02 – 2028-12-02 · Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
What this study did
NCT06557278 · Mirror Biologics, Inc.
2026-11 – 2028-11 · Metastatic Colorectal Cancer
What this study did
NCT06228066 · National Cancer Institute (NCI)
2024-06-13 – 2028-09-01 · Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract
What this study did
NCT04841148 · Abramson Cancer Center at Penn Medicine
2021-06-01 – 2028-05 · Breast Cancer
What this study did
NCT03076554 · National Cancer Institute (NCI)
2017-04-19 – 2028-03-30 · Thymoma, Thymic Carcinoma
What this study did
NCT06869473 · Gruppo Oncologico del Nord-Ovest
2025-02-20 – 2028-02-20 · Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
What this study did
NCT03979131 · Vall d'Hebron Institute of Oncology
2019-08-22 – 2027-06-15 · Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms
What this study did
NCT03414658 · Adrienne G. Waks
2018-06-21 – 2027-05-31 · Breast Cancer
What this study did
NCT03573648 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2018-11-13 – 2027-03-30 · Breast Cancer
What this study did
NCT03971409 · Laura Huppert, MD, BA
2019-07-08 – 2027-01-31 · Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
What this study did
NCT03391479 · University Health Network, Toronto
2018-08-15 – 2026-12-31 · Penile Cancer, Advanced Cancer, Metastatic Cancer
What this study did
NCT03147287 · Dana-Farber Cancer Institute
2017-09-05 – 2026-12-30 · Metastatic Breast Cancer
What this study did
Phase 1/2 (64)
Merkel Cell Carcinoma
NCT04261855 · Melanoma and Skin Cancer Trials Limited
2020-10-08 – 2027-12 · Metastatic Merkel Cell Carcinoma
What this study did
NCT06939036 · Ariceum Therapeutics GmbH
2025-07-01 – 2025-12-31 · Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
What this study did
NCT04260802 · Ocellaris Pharma, Inc.
2020-09-24 – 2025-11-07 · Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer, Gastric Cancer, Cervical Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Urothelial Neoplasm, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Locally Advanced Solid Tumor, Locally Advanced Malignant Neoplasm, Squamous Cell Carcinoma, Sarcoma, Merkel Cell Carcinoma, Bladder Cancer
What this study did
NCT03787602 · Kartos Therapeutics, Inc.
2019-03-19 – 2025-08 · Merkel Cell Carcinoma
What this study did
NCT04902040 · M.D. Anderson Cancer Center
2021-04-14 – 2025-02-27 · Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03167164 · ImmunityBio, Inc.
2017-12 – 2021-12-28 · Merkel Cell Carcinoma
What this study did
NCT02584829 · Fred Hutchinson Cancer Center
2015-11-06 – 2018-12-18 · Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7
What this study did
Urothelial Carcinoma
NCT03475953 · Institut Bergonié
2018-05-04 – 2025-12-31 · Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer, Hepatocellular Carcinoma, Soft-tissue Sarcoma, Thyroid Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Non-small Cell Lung Cancer, Solid Tumor, Adult, Urothelial Carcinoma, HPV-Related Carcinoma, Triple Negative Breast Cancer, Renal Carcinoma, Mesotheliomas Pleural
What this study did
NCT05687721 · VA Office of Research and Development
2025-06-02 – 2025-06-02 · Advanced Urothelial Carcinoma
What this study did
NCT03317496 · Pfizer
2017-12-21 – 2022-12-20 · Non-small Cell Lung Cancer, Urothelial Cancer
What this study did
Other / comorbidity
NCT02813135 · Gustave Roussy, Cancer Campus, Grand Paris
2016-08-03 – 2031-02 · Pediatric Cancer
What this study did
NCT05102721 · Vaccinex Inc.
2022-12-10 – 2028-12-31 · Metastatic Pancreatic Adenocarcinoma
What this study did
NCT04396223 · Hospices Civils de Lyon
2020-02-12 – 2028-10-12 · Gestational Trophoblastic Neoplasias (GTN)
What this study did
NCT02767063 · Versailles Hospital
2016-07 – 2028-06 · Leukemia, Myeloid, Chronic-Phase
What this study did
NCT03217747 · M.D. Anderson Cancer Center
2017-08-02 – 2028-04-30 · Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Refractory Malignant Solid Neoplasm, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
What this study did
NCT03707808 · Universitair Ziekenhuis Brussel
2018-01-29 – 2027-12-23 · Solid Tumor, Metastases to Soft Tissue
What this study did
NCT04068194 · National Cancer Institute (NCI)
2020-04-07 – 2027-07-01 · Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma, Locally Advanced Unresectable Malignant Solid Neoplasm, Metastatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Gallbladder Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
What this study did
NCT04071236 · National Cancer Institute (NCI)
2020-10-14 – 2027-04-30 · Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
What this study did
NCT03964532 · Georgetown University
2019-04-19 – 2027-04 · Breast Cancer
What this study did
NCT05267626 · Aulos Bioscience, Inc.
2022-04-04 – 2027-02-28 · Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
What this study did
NCT04266912 · M.D. Anderson Cancer Center
2020-03-17 – 2027-01-30 · Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
What this study did
NCT03260023 · Transgene
2017-09-01 – 2026-12 · HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma
What this study did
NCT02630368 · Institut Bergonié
2015-09-18 – 2024-11 · Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
What this study did
NCT03844763 · Gruppo Oncologico del Nord-Ovest
2019-01-07 – 2024-06-30 · Head and Neck Cancer
What this study did
NCT03747484 · Fred Hutchinson Cancer Center
2019-07-03 – 2024-01-09 · Other Skin
What this study did
NCT03892642 · University of Oklahoma
2019-05-01 – 2023-08-13 · Bladder Cancer
What this study did
NCT03490292 · University of Wisconsin, Madison
2018-05-29 – 2023-07-12 · Resectable Esophageal Cancer, GastroEsophageal Cancer
What this study did
NCT02554812 · Pfizer
2015-11-09 – 2023-03-23 · Advanced Cancer
What this study did
NCT03399552 · Memorial Sloan Kettering Cancer Center
2017-12-20 – 2023-01-20 · Malignant Mesothelioma (MPM)
What this study did
NCT03330405 · Pfizer
2017-10-19 – 2023-01-04 · Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
What this study did
NCT03750071 · Vaximm GmbH
2018-11-21 – 2022-12-31 · Recurrent Glioblastoma
What this study did
NCT03386929 · Worldwide Innovative Network Association
2017-11-29 – 2022-12-29 · Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
What this study did
NCT03409458 · Promontory Therapeutics Inc.
2018-04-24 – 2022-08-31 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT03390296 · M.D. Anderson Cancer Center
2017-12-27 – 2022-02-04 · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT03647423 · ImmunityBio, Inc.
2018-08-31 – 2021-12-28 · Chordoma, Unresectable Malignant Neoplasm
What this study did
NCT03169777 · ImmunityBio, Inc.
2018-08 – 2021-12-28 · Colorectal Cancer
What this study did
NCT03169790 · ImmunityBio, Inc.
2017-12 – 2021-12-23 · Non Hodgkin Lymphoma
What this study did
NCT02915523 · Syndax Pharmaceuticals
2016-12-19 – 2021-04-21 · Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
What this study did
NCT03637491 · Pfizer
2018-08-15 – 2021-02-02 · Pancreatic Cancer
What this study did
NCT03387111 · ImmunityBio, Inc.
2018-01-09 – 2021-01-11 · Squamous Cell Carcinoma
What this study did
NCT03074318 · Fred Hutchinson Cancer Center
2017-09-28 – 2020-11-15 · Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
What this study did
NCT03152565 · Grupo Espanol Multidisciplinario del Cancer Digestivo
2018-03-12 – 2020-10-05 · Colorectal Carcinoma
What this study did
Phase 1 (52)
Renal Cell Carcinoma
NCT03845166 · Exelixis
2019-03-20 – 2027-05-31 · Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
What this study did
NCT03200587 · University of Utah
2018-06-21 – 2021-11-25 · Renal Cell Carcinoma
What this study did
Urothelial Carcinoma
NCT06204614 · Brigham and Women's Hospital
2024-06-14 – 2028-08-01 · Muscle Invasive Bladder Urothelial Carcinoma
What this study did
NCT04004442 · University of Oklahoma
2020-02-17 – 2026-10 · Urothelial Carcinoma
What this study did
NCT03252938 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2017-08-15 – 2026-09-30 · Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma, Urothelial Carcinoma
What this study did
NCT03575013 · Yousef Zakharia
2018-10-29 – 2024-02-09 · Urothelial Carcinoma
What this study did
NCT04601402 · Genome & Company
2020-10-26 – 2023-01-11 · Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
What this study did
NCT03915405 · Kyowa Kirin, Inc.
2019-09-26 – 2022-11-15 · Urothelial Carcinoma
What this study did
Other / comorbidity
NCT04387084 · University of Southern California
2020-08-12 – 2028-03-31 · Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
What this study did
NCT04328844 · iOnctura
2020-02-25 – 2028-03 · Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis, Uveal Melanoma
What this study did
NCT04360941 · Royal Marsden NHS Foundation Trust
2020-08-11 – 2027-07-31 · Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT05222932 · TILT Biotherapeutics Ltd.
2023-03-08 – 2026-12 · Melanoma, Head and Neck Squamous Cell Carcinoma
What this study did
NCT03244176 · Austin Health
2017-07-21 – 2026-10-06 · Lymphomas Non-Hodgkin's B-Cell
What this study did
NCT05396833 · EMD Serono Research & Development Institute, Inc.
2022-06-07 – 2026-07-14 · Metastatic or Locally Advanced Unresectable Solid Tumors
What this study did
NCT06302426 · Inimmune Corporation
2024-07-01 – 2026-06-19 · Advanced Solid Tumor
What this study did
NCT05081180 · EMD Serono Research & Development Institute, Inc.
2021-12-03 – 2026-06-09 · Central Nervous System Tumors
What this study did
NCT03498378 · Kathryn Gold
2018-06-06 – 2025-12-30 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT04242238 · Memorial Sloan Kettering Cancer Center
2020-01-22 – 2025-08-26 · Sarcoma, Advanced Sarcoma, High Grade Sarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Dedifferentiated Liposarcoma
What this study did
NCT03893903 · German Cancer Research Center
2018-10-19 – 2024-09-20 · Malignant Glioma
What this study did
NCT03719768 · H. Lee Moffitt Cancer Center and Research Institute
2019-06-10 – 2024-08-21 · Leptomeningeal Metastases, Leptomeningeal Disease
What this study did
NCT03440567 · City of Hope Medical Center
2018-06-08 – 2024-06-24 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT05395052 · Fate Therapeutics
2022-05-31 – 2023-08-11 · Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
What this study did
NCT04551885 · Fate Therapeutics
2020-09-07 – 2023-08-11 · Solid Tumor, Adult
What this study did
NCT03636503 · Dana-Farber Cancer Institute
2018-10-30 – 2023-07-30 · Follicular Lymphoma
What this study did
NCT03267836 · Washington University School of Medicine
2018-01-10 – 2023-04-06 · Meningioma, Meningioma, Adult
What this study did
NCT03941262 · NKGen Biotech, Inc.
2019-07-15 – 2023-02-17 · Refractory Cancer, Metastatic Cancer, Recurrent Cancer, Unresectable Carcinoma, Solid Tumor, Adult, Advanced Cancer, Advanced Solid Tumor
What this study did
NCT03724890 · EMD Serono Research & Development Institute, Inc.
2018-11-27 – 2022-08-17 · Oncology, Solid Tumors
What this study did
NCT04065555 · Presage Biosciences
2020-10-07 – 2022-07-20 · Head and Neck Cancer
What this study did
NCT03905135 · National Cancer Institute (NCI)
2019-06-07 – 2022-05-17 · Peripheral T-cell Lymphoma NOS, Mycosis Fungoides, Sezary Syndrome, Anaplastic Large Cell Lymphoma
What this study did
NCT02923466 · Vyriad, Inc.
2017-04-17 – 2022-04-22 · Malignant Solid Tumour
What this study did
NCT03514719 · Radboud University Medical Center
2018-10-01 – 2021-12-02 · Non Small Cell Lung Cancer
What this study did
NCT03341806 · Icahn School of Medicine at Mount Sinai
2018-06-13 – 2021-10-13 · Glioblastoma, GBM
What this study did
NCT03451825 · EMD Serono Research & Development Institute, Inc.
2018-03-07 – 2021-07-27 · Refractory or Relapsed Solid Tumors, Lymphoma
What this study did
NCT02493751 · Pfizer
2015-10-26 – 2021-03-04 · Renal Cell Cancer
What this study did
NCT03483883 · Abramson Cancer Center at Penn Medicine
2018-03-19 – 2021-02-10 · Metastatic sRCC
What this study did
NCT03523390 · Merck KGaA, Darmstadt, Germany
2018-04-24 – 2021-02-08 · Metastatic Solid Tumors
What this study did
NCT02994953 · EMD Serono Research & Development Institute, Inc.
2017-01-31 – 2020-10-08 · Advanced Solid Tumors
What this study did
NCT03861403 · Leap Therapeutics, Inc.
2019-05-20 – 2020-07-14 · Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer, Advanced Platinum-Resistant Ovarian Cancer
What this study did
NCT03158883 · Megan Daly, MD
2017-05-17 – 2020-06-24 · Metastatic Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT01772004 · EMD Serono Research & Development Institute, Inc.
2013-01-31 – 2019-12-16 · Solid Tumors
What this study did
NCT03704467 · EMD Serono Research & Development Institute, Inc.
2019-03-04 – 2019-11-06 · Ovarian Cancer
What this study did
NCT02222922 · Pfizer
2014-10-17 – 2019-11-05 · Neoplasms
What this study did
NCT03289533 · Pfizer
2017-09-08 – 2019-10-25 · Carcinoma, Hepatocellular
What this study did
NCT03502681 · Monika Joshi, MD
2018-06-12 – 2019-10-25 · Metastatic Urothelial Cell Cancer
What this study did
NCT02938273 · The Netherlands Cancer Institute
2017-02-01 – 2019-09-30 · Carcinoma, Squamous Cell of Head and Neck
What this study did
NCT01943461 · Merck KGaA, Darmstadt, Germany
2013-09-02 – 2019-09-25 · Solid Tumors
What this study did
NCT03481920 · PH Research, S.L.
2018-01-10 – 2019-06-10 · Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
What this study did
NCT03395873 · Milton S. Hershey Medical Center
2018-01-29 – 2019-05-15 · Acute Myeloid Leukemia
What this study did
Phase 4 (1)
Urothelial Carcinoma
NCT06820255 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2025-01-07 – 2027-01-07 · Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable, Upper Tract Urothelial Cancer
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT06242522 · Hospices Civils de Lyon
2024-04-01 – 2025-04-01 · Gestational Trophoblastic Tumours, Immune Checkpoint Inhibitors
What this study did
NCT03826589 · The University of Hong Kong
2019-06-01 – 2024-07-01 · Cervical Cancer
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT02625623 · EMD Serono Research & Development Institute, Inc.
2015-12-28 – 2019-11-13 · Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
What this study did
Phase 2 (1)
Urothelial Carcinoma
NCT06225596 · BicycleTx Limited
2024-01-24 – 2028-03 · Metastatic Urothelial Cancer
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Renal Cell Carcinoma
NCT05327686 · NRG Oncology
2023-02-01 – 2033-06-15 · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT03944941 · Alliance for Clinical Trials in Oncology
2019-06-17 – 2028-12-01 · Skin Squamous Cell Carcinoma, Metastatic Skin Cancer
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Merkel Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Avelumab: this drugApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Atezolizumab
Approved(overall)
Monoclonal antibodyPD-L1
Partial signal(overall)
No reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT03783078: Objective Response Rate (ORR) (Up to ~34 months): Pembrolizumab 200 mg 49.1 Percentage of participants (95% CI 35.4 to 62.9)
NCT02267603: Objective Response Rate (ORR) Defined as the Proportion of Patients Who Have Achieved Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Up to 3 years): Treatment (Pembrolizumab) — Number participants with partial response (PR): 16 Participants; Number participants with complete response (CR): 12 Participants; Combined total participants with either PR or CR: 28 Participants
RetifanlimabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)
Approved(overall)
Monoclonal antibodyPD-L1
Partial signal(overall)
No reviewed efficacy summary in this indication
Adebrelimab
Phase 3(overall)
Monoclonal antibodyPD-L1
not yet graded(overall)
No reviewed efficacy summary in this indication
Envafolimab
Phase 3(overall)
Monoclonal antibodyPD-L1
Weak signal(overall)
No reviewed efficacy summary in this indication
Fetrastobart Vedotin
Phase 3(overall)
Antibody–drug conjugatePD-L1
not yet graded(overall)
No reviewed efficacy summary in this indication
Sugemalimab (Cejemly)
Phase 3(overall)
Monoclonal antibodyPD-L1
Reliable signal(overall)
No reviewed efficacy summary in this indication
Tagitanlimab
Phase 3(overall)
Monoclonal antibodyPD-L1
not yet graded(overall)
No reviewed efficacy summary in this indication
HLX43
Phase 2/3(overall)
Antibody–drug conjugatePD-L1
not yet graded(overall)
No reviewed efficacy summary in this indication
IFx-2.0Phase 2/3Gene therapy / editingInnate immune activation (intralesional plasmid DNA)not yet gradedNo reviewed efficacy summary in this indication
177Lu-RAD204
Phase 1(overall)
RadiopharmaceuticalPD-L1
not yet graded(overall)
No reviewed efficacy summary in this indication
BPI-371153
Phase 1(overall)
Small moleculePD-L1
not yet graded(overall)
No reviewed efficacy summary in this indication
IBC-Ab002
Phase 1(overall)
Monoclonal antibodyPD-L1
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Avelumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
November 2026 (1)
Phase 3Solid TumorsActive not recruiting
Est. primary completion 2026-11-24 · NCT03815643 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1Melanoma, Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT05222932 · CT.gov ↗
What to watch
Phase 1/2Merkel Cell CarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT04261855 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT03573648 · CT.gov ↗
What to watch
Phase 2Penile Cancer, Advanced Cancer, Metastatic CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT03391479 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT05059522 · CT.gov ↗
What to watch
2027 (19)
January 2027 (2)
Phase 2Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer …Active not recruiting
Est. primary completion 2027-01-31 · NCT03971409 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-01-31 · NCT03744793 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1/2Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-28 · NCT05267626 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Merkel Cell CarcinomaActive not recruiting
Est. primary completion 2027-03 · NCT04792073 · CT.gov ↗
What to watch
Phase 2Thymoma, Thymic CarcinomaActive not recruiting
Est. primary completion 2027-03-30 · NCT03076554 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1/2Breast CancerActive not recruiting
Est. primary completion 2027-04 · NCT03964532 · CT.gov ↗
What to watch
Phase 1/2Solid Tumor, Metastases to Soft TissueActive not recruiting
Est. primary completion 2027-04-23 · NCT03707808 · CT.gov ↗
What to watch
Phase 1/2Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone …Active not recruiting
Est. primary completion 2027-04-30 · NCT04071236 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2027-06-30 · NCT06892860 · CT.gov ↗
What to watch
July 2027 (3)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-07 · NCT04841148 · CT.gov ↗
What to watch
Phase 1/2Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma …Active not recruiting
Est. primary completion 2027-07-01 · NCT04068194 · CT.gov ↗
What to watch
Phase 1Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer …Active not recruiting
Est. primary completion 2027-07-31 · NCT04360941 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck CancerRecruiting
Est. primary completion 2027-08-20 · NCT06869473 · CT.gov ↗
What to watch
Phase 2Endometrial Cancer, ARID1A Gene Mutation, Recurrent Endometrial CarcinomaActive not recruiting
Est. primary completion 2027-08-31 · NCT06518564 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary TractRecruiting
Est. primary completion 2027-09-01 · NCT06228066 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Recurrent or Metastatic Squamous Cell Carcinoma of Head and NeckRecruiting
Est. primary completion 2027-10-02 · NCT06640725 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1/2Leukemia, Myeloid, Chronic-PhaseActive not recruiting
Est. primary completion 2027-12 · NCT02767063 · CT.gov ↗
What to watch
Phase 3HNSCCActive not recruiting
Est. primary completion 2027-12 · NCT02999087 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 2Merkel Cell CarcinomaActive not recruiting
Est. primary completion 2028-01-01 · NCT05947500 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1Urothelial CarcinomaEnrolling by invitation
Est. primary completion 2028-07-01 · NCT06204614 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2Metastatic Pancreatic AdenocarcinomaActive not recruiting
Est. primary completion 2028-12-31 · NCT05102721 · CT.gov ↗
What to watch
2029 (5)
January 2029 (1)
Phase 3Merkel Cell CarcinomaActive not recruiting
Est. primary completion 2029-01-31 · NCT03271372 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Cancer, Tumors, Neoplasms, NeoplasiaRecruiting
Est. primary completion 2029-04-30 · NCT04341181 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Penile Squamous Cell Carcinoma (PSCC)Recruiting
Est. primary completion 2029-05 · NCT07110038 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Urothelial CarcinomaActive not recruiting
Est. primary completion 2029-07-15 · NCT05092958 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Merkel Cell CarcinomaActive not recruiting
Est. primary completion 2029-08-31 · NCT03228667 · CT.gov ↗
What to watch
2030 (1)
April 2030 (1)
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2030-04 · NCT03547973 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
Phase 1/2Pediatric CancerRecruiting
Est. primary completion 2031-02 · NCT02813135 · CT.gov ↗
What to watch

See the full readout calendar ↗